vs
Side-by-side financial comparison of BGSF, INC. (BGSF) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.
GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $22.0M, roughly 1.7× BGSF, INC.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -5.3%, a 1.6% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -9.4%). BGSF, INC. produced more free cash flow last quarter ($1.7M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs -5.3%).
BGSF Inc. is a leading U.S.-headquartered workforce solutions firm that provides tailored staffing, talent recruitment, and end-to-end workforce management services. It serves core segments including information technology, healthcare, professional administration, light industrial, and creative industries, catering to small, mid-sized and large enterprise clients across North America.
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
BGSF vs GYRE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $22.0M | $37.2M |
| Net Profit | $-1.2M | $-1.4M |
| Gross Margin | 35.0% | 95.3% |
| Operating Margin | -17.6% | 0.3% |
| Net Margin | -5.3% | -3.7% |
| Revenue YoY | -9.4% | 33.4% |
| Net Profit YoY | -18.2% | -340.1% |
| EPS (diluted) | $-0.12 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $22.0M | $37.2M | ||
| Q3 25 | $26.9M | $30.6M | ||
| Q2 25 | $23.5M | $26.8M | ||
| Q1 25 | $20.9M | $22.1M | ||
| Q4 24 | $24.3M | $27.9M | ||
| Q3 24 | $29.8M | $25.5M | ||
| Q2 24 | $25.7M | $25.2M | ||
| Q1 24 | $24.5M | $27.2M |
| Q4 25 | $-1.2M | $-1.4M | ||
| Q3 25 | $-5.8M | $5.9M | ||
| Q2 25 | $-3.7M | $1.6M | ||
| Q1 25 | $-722.0K | $3.7M | ||
| Q4 24 | $-981.0K | $569.0K | ||
| Q3 24 | $-804.0K | $2.9M | ||
| Q2 24 | $-761.0K | $4.5M | ||
| Q1 24 | $-792.0K | $9.9M |
| Q4 25 | 35.0% | 95.3% | ||
| Q3 25 | 35.9% | 94.7% | ||
| Q2 25 | 35.8% | 95.7% | ||
| Q1 25 | 36.2% | 95.9% | ||
| Q4 24 | 35.9% | 95.8% | ||
| Q3 24 | 35.9% | 96.2% | ||
| Q2 24 | 37.3% | 96.9% | ||
| Q1 24 | 38.1% | 96.4% |
| Q4 25 | -17.6% | 0.3% | ||
| Q3 25 | -3.5% | 22.7% | ||
| Q2 25 | -18.8% | 8.1% | ||
| Q1 25 | 1.6% | 10.3% | ||
| Q4 24 | -15.7% | 2.4% | ||
| Q3 24 | -3.4% | 16.6% | ||
| Q2 24 | -5.7% | 12.7% | ||
| Q1 24 | 1.7% | 29.7% |
| Q4 25 | -5.3% | -3.7% | ||
| Q3 25 | -21.6% | 19.4% | ||
| Q2 25 | -15.9% | 5.9% | ||
| Q1 25 | -3.5% | 16.9% | ||
| Q4 24 | -4.0% | 2.0% | ||
| Q3 24 | -2.7% | 11.2% | ||
| Q2 24 | -3.0% | 18.0% | ||
| Q1 24 | -3.2% | 36.6% |
| Q4 25 | $-0.12 | $-0.01 | ||
| Q3 25 | $-0.52 | $0.03 | ||
| Q2 25 | $-0.34 | $0.00 | ||
| Q1 25 | $-0.06 | $0.00 | ||
| Q4 24 | — | $0.00 | ||
| Q3 24 | $-0.07 | $0.01 | ||
| Q2 24 | $-0.07 | $0.01 | ||
| Q1 24 | — | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $52.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.1M | $106.0M |
| Total Assets | $57.8M | $166.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $52.4M | ||
| Q3 25 | $41.2M | $60.0M | ||
| Q2 25 | $2.8M | $54.4M | ||
| Q1 25 | $2.0M | $29.9M | ||
| Q4 24 | $32.0K | $26.7M | ||
| Q3 24 | $262 | $25.1M | ||
| Q2 24 | $226 | $25.1M | ||
| Q1 24 | $50 | $37.4M |
| Q4 25 | $48.1M | $106.0M | ||
| Q3 25 | $50.7M | $101.9M | ||
| Q2 25 | $78.3M | $92.0M | ||
| Q1 25 | $81.8M | $68.1M | ||
| Q4 24 | $82.3M | $63.3M | ||
| Q3 24 | $82.9M | $63.2M | ||
| Q2 24 | $83.2M | $60.4M | ||
| Q1 24 | $83.6M | $56.6M |
| Q4 25 | $57.8M | $166.1M | ||
| Q3 25 | $83.6M | $159.4M | ||
| Q2 25 | $149.7M | $152.6M | ||
| Q1 25 | $152.3M | $129.8M | ||
| Q4 24 | $150.1M | $125.4M | ||
| Q3 24 | $157.3K | $125.2M | ||
| Q2 24 | $159.8K | $120.9M | ||
| Q1 24 | $170.6K | $122.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.7M | $-5.6M |
| Free Cash FlowOCF − Capex | $1.7M | $-5.8M |
| FCF MarginFCF / Revenue | 7.6% | -15.5% |
| Capex IntensityCapex / Revenue | 0.1% | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-16.0K | $-180.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | $-5.6M | ||
| Q3 25 | $-4.8M | $4.7M | ||
| Q2 25 | $2.2M | $2.1M | ||
| Q1 25 | $1.1M | $-129.0K | ||
| Q4 24 | $3.2M | $-2.8M | ||
| Q3 24 | $6.5M | $1.7M | ||
| Q2 24 | $7.3M | $-5.5M | ||
| Q1 24 | $7.4M | $2.9M |
| Q4 25 | $1.7M | $-5.8M | ||
| Q3 25 | $-4.9M | $4.0M | ||
| Q2 25 | $2.1M | $1.8M | ||
| Q1 25 | $1.0M | $-251.0K | ||
| Q4 24 | $2.5M | $-2.8M | ||
| Q3 24 | $6.5M | $1.0M | ||
| Q2 24 | $7.3M | $-6.9M | ||
| Q1 24 | $6.9M | $2.7M |
| Q4 25 | 7.6% | -15.5% | ||
| Q3 25 | -18.1% | 13.1% | ||
| Q2 25 | 9.1% | 6.8% | ||
| Q1 25 | 5.0% | -1.1% | ||
| Q4 24 | 10.2% | -10.1% | ||
| Q3 24 | 21.7% | 4.1% | ||
| Q2 24 | 28.5% | -27.5% | ||
| Q1 24 | 28.1% | 9.8% |
| Q4 25 | 0.1% | 0.4% | ||
| Q3 25 | 0.4% | 2.2% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.1% | 0.6% | ||
| Q4 24 | 3.0% | 0.2% | ||
| Q3 24 | 0.0% | 2.7% | ||
| Q2 24 | 0.0% | 5.8% | ||
| Q1 24 | 2.0% | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.79× | ||
| Q2 25 | — | 1.32× | ||
| Q1 25 | — | -0.03× | ||
| Q4 24 | — | -4.85× | ||
| Q3 24 | — | 0.60× | ||
| Q2 24 | — | -1.21× | ||
| Q1 24 | — | 0.29× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BGSF
| Contract Field Talent | $21.4M | 97% |
| Other | $595.0K | 3% |
GYRE
Segment breakdown not available.
